Washington-based Stemgenics specializes in converting mature cells into personalized stem cells for regenerative medicine by exposing individuals’ cells to its patented functionalized nanoparticles that do not contain DNA or viruses. Personalized pluripotent stem cells may be differentiated into any cell type of the human body. In addition, Stemgenics has developed a technology that directly re-programs mature cells from a skin patch or a blood draw into liver or heart cells using its functionalized nanoparticles, that are DNA and virus-free. This approach saves time and money. “Our functionally active nanoparticle reprogramming technology has tremendous potential, which is not limited to clinical regenerative medicine but maybe broadly used, including the treatment of rare genetic diseases,” says Dr. Frederick S. Hagen, CEO of Stemgenics.
The current treatment for liver and heart failure is organ transplantation, but with the limited number of livers and hearts available, most of these patients remain untreated. With Stemgenics’ groundbreaking solution for tissue regeneration, Stemgenics realizes that this approach will save many lives and increase the quality of life for the large number of people suffering from liver or heart failure, who are unable to be treated due to lack of organs for transplant. Stemgenics is currently in a round of equity financing to fund clinical trials for liver and heart regeneration.